Cargando…
Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study
PURPOSE: To describe patients’ perspectives on the use of and potential challenges and barriers with adherence/persistence to cyclin-dependent kinase 4 and 6 inhibitors (CDK4&6i’s) to treat metastatic breast cancer (MBC). METHODS: This qualitative study consisted of 60-minute semi-structured tel...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573215/ https://www.ncbi.nlm.nih.gov/pubmed/34764640 http://dx.doi.org/10.2147/PPA.S319239 |
_version_ | 1784595374232567808 |
---|---|
author | Stephenson, Judith J Gable, Jonathon Colby Zincavage, Rebekah Price, Gregory L Churchill, Collin Zhu, Emily Stenger, Keri Singhal, Mukul Nepal, Bal Grabner, Michael Fisch, Michael J Debono, David Geschwender, Amy R Cuyun Carter, Gebra |
author_facet | Stephenson, Judith J Gable, Jonathon Colby Zincavage, Rebekah Price, Gregory L Churchill, Collin Zhu, Emily Stenger, Keri Singhal, Mukul Nepal, Bal Grabner, Michael Fisch, Michael J Debono, David Geschwender, Amy R Cuyun Carter, Gebra |
author_sort | Stephenson, Judith J |
collection | PubMed |
description | PURPOSE: To describe patients’ perspectives on the use of and potential challenges and barriers with adherence/persistence to cyclin-dependent kinase 4 and 6 inhibitors (CDK4&6i’s) to treat metastatic breast cancer (MBC). METHODS: This qualitative study consisted of 60-minute semi-structured telephone interviews with patients with MBC in the US who were either current or recent CDK4&6i users, identified from administrative claims of survey-eligible commercial and Medicare Advantage patients in the HealthCore Integrated Research Database between November 1, 2018 and November 1, 2019. Patients were recruited by email and/or mailed letter. The 60-minute telephone interviews were conducted by a trained facilitator using a study-developed interview discussion guide that included topics impacting treatment choice and adherence/persistence. Interviews were audio-recorded, transcribed, and thematically analyzed. RESULTS: All 462 eligible patients were sent a recruitment email and/or letter to which 36 patients responded, consented to participate, and met study inclusion criteria; 25 patients scheduled interviews, and 24 completed them. Study participants were predominately white, non-Hispanic (96%) with a mean age of 59.5 years. Participants reported a largely positive experience and mentioned very few adherence/persistence issues. They further reported appreciating the ease and convenience of oral oncolytics, coped with side effects, had strong medical and social support, and experienced few cost issues. CONCLUSION: The few adherence/persistence issues reported by participants contrasts with other findings of suboptimal oral oncolytic use. Interview themes indicated several factors that likely contributed to the lack of adherence/persistence issues: trusted relationship with oncologist, belief in importance of medication, positive medication views, strong medical and social support, and minimal personal drug cost. Future research should focus on whether and how much these factors impact adherence/persistence in more diverse populations. If adherence/persistence issues are identified in these populations, then it would be appropriate to study the development of interventions that target factors associated with better adherence/persistence. |
format | Online Article Text |
id | pubmed-8573215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-85732152021-11-10 Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study Stephenson, Judith J Gable, Jonathon Colby Zincavage, Rebekah Price, Gregory L Churchill, Collin Zhu, Emily Stenger, Keri Singhal, Mukul Nepal, Bal Grabner, Michael Fisch, Michael J Debono, David Geschwender, Amy R Cuyun Carter, Gebra Patient Prefer Adherence Original Research PURPOSE: To describe patients’ perspectives on the use of and potential challenges and barriers with adherence/persistence to cyclin-dependent kinase 4 and 6 inhibitors (CDK4&6i’s) to treat metastatic breast cancer (MBC). METHODS: This qualitative study consisted of 60-minute semi-structured telephone interviews with patients with MBC in the US who were either current or recent CDK4&6i users, identified from administrative claims of survey-eligible commercial and Medicare Advantage patients in the HealthCore Integrated Research Database between November 1, 2018 and November 1, 2019. Patients were recruited by email and/or mailed letter. The 60-minute telephone interviews were conducted by a trained facilitator using a study-developed interview discussion guide that included topics impacting treatment choice and adherence/persistence. Interviews were audio-recorded, transcribed, and thematically analyzed. RESULTS: All 462 eligible patients were sent a recruitment email and/or letter to which 36 patients responded, consented to participate, and met study inclusion criteria; 25 patients scheduled interviews, and 24 completed them. Study participants were predominately white, non-Hispanic (96%) with a mean age of 59.5 years. Participants reported a largely positive experience and mentioned very few adherence/persistence issues. They further reported appreciating the ease and convenience of oral oncolytics, coped with side effects, had strong medical and social support, and experienced few cost issues. CONCLUSION: The few adherence/persistence issues reported by participants contrasts with other findings of suboptimal oral oncolytic use. Interview themes indicated several factors that likely contributed to the lack of adherence/persistence issues: trusted relationship with oncologist, belief in importance of medication, positive medication views, strong medical and social support, and minimal personal drug cost. Future research should focus on whether and how much these factors impact adherence/persistence in more diverse populations. If adherence/persistence issues are identified in these populations, then it would be appropriate to study the development of interventions that target factors associated with better adherence/persistence. Dove 2021-11-03 /pmc/articles/PMC8573215/ /pubmed/34764640 http://dx.doi.org/10.2147/PPA.S319239 Text en © 2021 Stephenson et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Stephenson, Judith J Gable, Jonathon Colby Zincavage, Rebekah Price, Gregory L Churchill, Collin Zhu, Emily Stenger, Keri Singhal, Mukul Nepal, Bal Grabner, Michael Fisch, Michael J Debono, David Geschwender, Amy R Cuyun Carter, Gebra Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study |
title | Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study |
title_full | Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study |
title_fullStr | Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study |
title_full_unstemmed | Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study |
title_short | Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study |
title_sort | treatment experiences with cdk4&6 inhibitors among women with metastatic breast cancer: a qualitative study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573215/ https://www.ncbi.nlm.nih.gov/pubmed/34764640 http://dx.doi.org/10.2147/PPA.S319239 |
work_keys_str_mv | AT stephensonjudithj treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT gablejonathoncolby treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT zincavagerebekah treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT pricegregoryl treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT churchillcollin treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT zhuemily treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT stengerkeri treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT singhalmukul treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT nepalbal treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT grabnermichael treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT fischmichaelj treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT debonodavid treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT geschwenderamyr treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy AT cuyuncartergebra treatmentexperienceswithcdk46inhibitorsamongwomenwithmetastaticbreastcanceraqualitativestudy |